SG startup K25 AI secures $2M from Nasdaq-listed Semler Scientific for enterprise AI push

Singapore's AI startup ecosystem continues to attract global capital, with the latest vote of confidence going to K25 AI, a homegrown enterprise AI company that has secured US$2 million in funding from Nasdaq-listed healthcare technology firm Semler Scientific. The investment underscores a broader shift in how institutional investors are thinking about AI — away from speculative moonshots and toward startups with clear commercial use cases and measurable ROI.

K25 AI builds products that leverage generative AI and automation to improve healthcare workflows, operational efficiency, and enterprise decision-making. Its tools help organisations with data analysis, workflow management, and intelligent process optimisation — the kind of bread-and-butter AI applications that are seeing the fastest adoption in enterprise settings. The company plans to use the fresh capital to scale its engineering team, accelerate product development, and expand into international markets, particularly in healthcare and adjacent verticals.

The deal is notable for several reasons. Semler Scientific, a publicly traded healthcare technology company, is placing a strategic bet on Singapore as a hub for applied AI. This mirrors a pattern seen across the region in 2026: healthcare has emerged as one of the fastest-growing sectors for AI adoption globally, driven by demand for administrative automation, predictive analytics, and better patient management tools. For a Singapore startup to land a Nasdaq-listed strategic investor signals that local AI companies can compete on a global stage — not just on cost, but on technical capability and product maturity.

The investment also reflects the maturation of Singapore's AI ecosystem more broadly. Government-backed programmes, infrastructure investments, and talent development initiatives have created a fertile ground for enterprise AI startups to grow. K25 AI's ability to attract a US-listed strategic investor — as opposed to a traditional VC round — suggests that Singapore-based AI companies are increasingly seen as viable long-term partners by global corporates looking to integrate AI into their operations.

Why it matters for Singapore: Every time a Singapore AI startup attracts a marquee international investor, it validates the thesis that the city-state can produce commercially relevant AI companies — not just research and talent. K25 AI's $2 million round is relatively small compared to the mega-rounds seen in Silicon Valley, but the source of the capital (a Nasdaq-listed healthcare firm) is arguably more significant than the amount. It suggests a pathway to commercial partnerships and acquisition targets that goes beyond the traditional VC-to-IPO pipeline. For founders building enterprise AI in Singapore, it's a signal that practical, outcome-focused products can attract strategic capital from global players.